Dossier assessment
Benralizumab (asthma) - Benefit assessment according to §35a Social Code Book V
Report documents
-
Extract of dossier assessment
Benralizumab (asthma) - Benefit assessment according to §35a Social Code Book V
-
Dossier assessment
Benralizumab (asthma) - Benefit assessment according to §35a Social Code Book V
Dossier assessment
Add-on maintenance treatment in adults with severe eosinophilic asthma inadequately controlled despite high-dose inhaled corticosteroids plus long-acting beta agonists
Added benefit not proven due to lack of suitable study data
Additional information
Federal Joint Committee (G-BA)
2018-08-02 A G-BA decision was published.
Project details
- Project no.
- A18-11
- Commission
- Commission awarded on 15.02.2018 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Airways and respiratory system
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
Connected Projects
-
Dossier assessment
Benralizumab (eosinophilic granulomatosis with polyangiitis) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Benralizumab (hypereosinophilic syndrome) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed